$0.71 EPS Expected for Abbott Laboratories (ABT)

June 15, 2018 - By Carrie Sands

Abbott Laboratories (NYSE:ABT) LogoInvestors sentiment decreased to 0.83 in 2018 Q1. Its down 0.08, from 0.91 in 2017Q4. It is negative, as 44 investors sold Abbott Laboratories shares while 606 reduced holdings. 126 funds opened positions while 411 raised stakes. 1.22 billion shares or 0.54% more from 1.22 billion shares in 2017Q4 were reported.
Chemung Canal Tru Co invested 0.42% in Abbott Laboratories (NYSE:ABT). Hugh Johnson Advsrs Ltd stated it has 1.2% of its portfolio in Abbott Laboratories (NYSE:ABT). Fort Point Cap Partners Limited Liability Corp holds 0.06% of its portfolio in Abbott Laboratories (NYSE:ABT) for 4,004 shares. Dimensional Fund Advsrs L P holds 9.41M shares. Adell Harriman Carpenter owns 7,033 shares or 0% of their US portfolio. Foothills Asset invested in 1.16% or 24,745 shares. Moreover, Griffin Asset Mngmt has 1.42% invested in Abbott Laboratories (NYSE:ABT). Vanguard Grp Incorporated holds 0.35% or 134.09 million shares in its portfolio. Mariner Wealth owns 252,629 shares or 0.93% of their US portfolio. Mengis Capital Management has invested 0.23% in Abbott Laboratories (NYSE:ABT). 1.21 million are owned by Pub Employees Retirement Association Of Colorado. Lvw Advisors Limited accumulated 4,355 shares or 0.08% of the stock. 18,760 were reported by Duff Phelps Mgmt. Churchill Mgmt has 0.08% invested in Abbott Laboratories (NYSE:ABT). Fragasso Group Inc reported 0.07% in Abbott Laboratories (NYSE:ABT).

Since January 30, 2018, it had 1 insider purchase, and 20 selling transactions for $22.32 million activity. Salvadori Daniel Gesua Sive sold $183,592 worth of stock or 3,000 shares. Another trade for 459 shares valued at $27,213 was made by PEDERSON MICHAEL J on Friday, February 16. Funck Robert E also sold $71,970 worth of Abbott Laboratories (NYSE:ABT) shares. On Monday, March 5 the insider Bracken Sharon J sold $126,559. STARKS DANIEL J had bought 40,037 shares worth $2.43M. MANNING JOSEPH J also sold $84,344 worth of Abbott Laboratories (NYSE:ABT) shares.

Analysts expect Abbott Laboratories (NYSE:ABT) to report $0.71 EPS on July, 19.They anticipate $0.09 EPS change or 14.52 % from last quarter’s $0.62 EPS. ABT’s profit would be $1.24 billion giving it 22.17 P/E if the $0.71 EPS is correct. After having $0.59 EPS previously, Abbott Laboratories’s analysts see 20.34 % EPS growth. The stock increased 0.53% or $0.33 during the last trading session, reaching $62.96. About 3.98 million shares traded. Abbott Laboratories (NYSE:ABT) has risen 41.91% since June 15, 2017 and is uptrending. It has outperformed by 29.34% the S&P500.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Among 14 analysts covering Abbott Laboratories (NYSE:ABT), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. Abbott Laboratories had 19 analyst reports since January 2, 2018 according to SRatingsIntel. Morgan Stanley maintained the shares of ABT in report on Thursday, January 25 with “Overweight” rating. The stock has “Buy” rating by RBC Capital Markets on Wednesday, January 24. JP Morgan upgraded Abbott Laboratories (NYSE:ABT) on Tuesday, January 2 to “Overweight” rating. Guggenheim maintained the stock with “Buy” rating in Thursday, January 25 report. The rating was maintained by Barclays Capital with “Overweight” on Thursday, January 25. As per Thursday, January 25, the company rating was maintained by Wells Fargo. The rating was maintained by Stifel Nicolaus with “Buy” on Wednesday, January 24. The stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given on Wednesday, January 24 by BMO Capital Markets. The rating was maintained by JP Morgan with “Overweight” on Thursday, January 25. The rating was upgraded by Morgan Stanley on Tuesday, January 2 to “Overweight”.

Abbott Laboratories manufactures and sells health care products worldwide. The company has market cap of $110.38 billion. The companyÂ’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon. It has a 235.81 P/E ratio. The Company’s Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic tests; informatics and automation solutions; and a suite of informatics tools and professional services.

More news for Abbott Laboratories (NYSE:ABT) were recently published by: Investorplace.com, which released: “10 Dividend Aristocrats You Never Have to Worry About” on June 13, 2018. Globenewswire.com‘s article titled: “Report: Developing Opportunities within Abbott Laboratories, Markel, Microsoft, Gazit-Globe, National General, and …” and published on June 14, 2018 is yet another important article.

Abbott Laboratories (NYSE:ABT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.